Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detailed overview on rare malignant ovarian tumors.
Aust S, Eberst L, Tredan O, Rousset-Jablonski C, Treilleux I, Méeus P, Chopin N, Beurrier F, Charreton A, Véronique D, Hallouz A, Coulon A, Ricoeur A, Mastier C, Bouhamama A, Racadot S, Devouassoux-Shisheboran M, Haddad V, Ray-Coquard I. Aust S, et al. Among authors: eberst l. Bull Cancer. 2020 Mar;107(3):385-390. doi: 10.1016/j.bulcan.2020.01.011. Epub 2020 Feb 27. Bull Cancer. 2020. PMID: 32115180 Review.
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I. Eberst L, et al. BMC Cancer. 2014 Nov 24;14:870. doi: 10.1186/1471-2407-14-870. BMC Cancer. 2014. PMID: 25420707 Free PMC article. Clinical Trial.
[Therapeutic targeting of Notch signaling in cancer].
Brahmi M, Bally O, Eberst L, Cassier P. Brahmi M, et al. Among authors: eberst l. Bull Cancer. 2017 Oct;104(10):883-891. doi: 10.1016/j.bulcan.2017.07.007. Epub 2017 Oct 12. Bull Cancer. 2017. PMID: 29031504 Review. French.
[DNA repair as a therapeutic target].
Eberst L, Brahmi M, Cassier PA. Eberst L, et al. Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11. Bull Cancer. 2017. PMID: 29132681 Review. French.
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, Cassier P, Eberst L, Steineur MP, Kazes M, Perol M, Michallet AS, Rey P, Erena-Penet AS, Morel A, Brahmi M, Dufresne A, Tredan O, Chvetzoff G, Fayette J, de la Fouchardiere C, Ray-Coquard I, Bachelot T, Saintigny P, Tabutin M, Dupré A, Nicolas-Virelizier E, Belhabri A, Roux PE, Fuhrmann C, Pilleul F, Basle A, Bouhamama A, Galvez C, Herr AL, Gautier J, Chabaud S, Zrounba P, Perol D, Blay JY. Assaad S, et al. Among authors: eberst l. Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7. Eur J Cancer. 2020. PMID: 32540204 Free PMC article.
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial.
Arnaud-Coffin P, Brahmi M, Vanacker H, Eberst L, Tredan O, Attignon V, Pissaloux D, Sohier E, Cassier P, Garin G, Pérol D, Blay JY, Dufresne A. Arnaud-Coffin P, et al. Among authors: eberst l. Transl Oncol. 2020 Dec;13(12):100870. doi: 10.1016/j.tranon.2020.100870. Epub 2020 Sep 18. Transl Oncol. 2020. PMID: 32950930 Free PMC article.
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.
Heudel P, Chabaud S, Perol D, Flechon A, Fayette J, Combemale P, Tredan O, Desseigne F, de la Fouchardiere C, Boyle H, Perol M, Bachelot T, Cassier P, Avrillon V, Terret C, Michallet AS, Neidhardt-Berard EM, Nicolas-Virelizier E, Dufresne A, Belhabri A, Brahmi M, Lebras L, Nicolini F, Sarabi M, Rey P, Bonneville-Levard A, Rochefort P, Provensal AM, Eberst L, Assaad S, Swalduz A, Saintigny P, Toussaint P, Guillermin Y, Castets M, Coutzac C, Meeus P, Dupré A, Durand T, Crochet H, Fervers B, Gomez F, Rivoire M, Gregoire V, Claude L, Chassagne-Clement C, Pilleul F, Mognetti T, Russias B, Soubirou JL, Lasset C, Chvetzoff G, Mehlen P, Beaupère S, Zrounba P, Ray-Coquard I, Blay JY. Heudel P, et al. Among authors: eberst l. ESMO Open. 2021 Feb;6(1):100044. doi: 10.1016/j.esmoop.2020.100044. Epub 2021 Jan 27. ESMO Open. 2021. PMID: 33516148 Free PMC article.
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Cassier PA, et al. Among authors: eberst l. Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. Transl Oncol. 2022. PMID: 34794033 Free PMC article.
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O. Bonnet E, et al. Among authors: eberst l. J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595. J Pers Med. 2022. PMID: 36294734 Free PMC article.
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Berthel E, Vincent A, Eberst L, Torres AG, Dacheux E, Rey C, Marcel V, Paraqindes H, Lachuer J, Catez F, Pouplana LR, Treilleux I, Diaz JJ, Venezia ND. Berthel E, et al. Among authors: eberst l. Cells. 2020 Apr 10;9(4):941. doi: 10.3390/cells9040941. Cells. 2020. PMID: 32290274 Free PMC article.
32 results